MaxCyte Inc MXCT Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$1.26 down $0.05, 3.82% at close Nov 6
Last close · Previous close $1.31
- Market cap
- $134.97MAt the Nov 6 close
- P/E ratio
- On last 12 months’ EPS
- Diluted EPS
- Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$1.26down $0.05, 3.82%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$1.31Nov 5
- Volume876.55KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.68MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.64 to $1.81; now $1.26
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
MXCT beat the S&P 500 in 2 of 6 periods.
| Period | MXCT and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | MXCT: up 15.6% S&P 500: down 5.6% | MXCT beat the S&P 500 by 21.2 percentage points Beat |
| 3M | MXCT: up 13.5% S&P 500: down 4.1% | MXCT beat the S&P 500 by 17.6 percentage points Beat |
| YTD | MXCT: down 18.7% S&P 500: up 8.7% | MXCT trailed the S&P 500 by 27.4 percentage points Trailed |
| 1Y | MXCT: down 14.3% S&P 500: up 10.9% | MXCT trailed the S&P 500 by 25.2 percentage points Trailed |
| Long term | ||
| 3Y | MXCT: down 64.0% S&P 500: up 75.0% −28.9% vs +20.5% a year | MXCT trailed the S&P 500 by 139.0 percentage points Trailed |
| 5Y | MXCT: down 88.9% S&P 500: up 67.8% −35.6% vs +10.9% a year | MXCT trailed the S&P 500 by 156.7 percentage points Trailed |
$10,000 invested in MXCT 5 years ago (Nov 5, 2021) would be worth about $1,108 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
MXCT beat the S&P 500 in 2 of 6 periods.
| Period | MXCT and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | MXCT: up 15.6% S&P 500: down 5.6% | MXCT beat the S&P 500 by 21.2 percentage points Beat |
| 3M | MXCT: up 13.5% S&P 500: down 4.3% | MXCT beat the S&P 500 by 17.8 percentage points Beat |
| YTD | MXCT: down 18.7% S&P 500: up 7.8% | MXCT trailed the S&P 500 by 26.5 percentage points Trailed |
| 1Y | MXCT: down 14.3% S&P 500: up 9.7% | MXCT trailed the S&P 500 by 24.0 percentage points Trailed |
| Long term | ||
| 3Y | MXCT: down 64.0% S&P 500: up 68.8% −28.9% vs +19.1% a year | MXCT trailed the S&P 500 by 132.8 percentage points Trailed |
| 5Y | MXCT: down 88.9% S&P 500: up 56.9% −35.6% vs +9.4% a year | MXCT trailed the S&P 500 by 145.8 percentage points Trailed |
$10,000 invested in MXCT 5 years ago (Nov 5, 2021) would be worth about $1,108 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$17.20
Closing high on . Now 92.7% below that record.
Split-adjusted daily closes since Dec 5, 2019.
Stock splits
MXCT hasn’t split since its price history begins in 2019.
Valuation
Financials
About MaxCyte Inc
MaxCyte, the clinical-stage global cell-based therapies and life sciences company, uses its proprietary next-generation cell and gene therapies to revolutionise medical treatments and ultimately save lives. The Company’s premier cell engineering enabling technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted to more than 100 cell therapy programmes, with more than 70 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (AIM:MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US.
- Sector
- Industry
- Headquarters
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
MXCT news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
MXCT stock FAQ
What is MXCT stock’s price today?
MaxCyte (MXCT) traded at $1.26 at the close on , down $0.05 (3.82%) from the previous close of $1.31. Over the past 52 weeks it has traded between $0.64 and $1.81.
If you invested $1,000 in MXCT 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in MXCT on would be worth about $111 at the close on , a total return of −88.9%. The same $1,000 would be worth $857 if invested one year ago. Past performance doesn’t predict future returns.
What is MaxCyte’s market cap?
MaxCyte’s market capitalization is about $135.0 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $1.26 (how market cap works).
Does MXCT pay a dividend?
MaxCyte hasn’t paid a dividend in the last twelve months.
What is MXCT’s 52-week high and low?
Over the past 52 weeks MXCT has traded as low as $0.64 and as high as $1.81. At $1.26 at the close on , it is 30.2% below that high and 95.8% above the low.
What is MXCT’s all-time high?
MXCT’s highest closing price was $17.20 on , adjusted for stock splits. At $1.26 at the close on , it is 92.7% below that record.
Has MXCT stock ever split?
No. MXCT hasn’t split since its price history begins in 2019.
How has MXCT stock performed?
Including dividends and measured to the close on , MXCT has returned −18.7% so far this year and −14.3% over the past year, and −88.9% over five years (−35.6% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What exchange does MXCT trade on?
MaxCyte trades on the Nasdaq under the ticker symbol MXCT. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.